Jan Van Overbeeke
Jan van Overbeeke, M.Sc., MBA, based in Tokyo, co-leads Medical Affairs for McKinsey across Asia. As part of his work, he provides leadership in client service on medical topics across the Asia region, publishes in the public domain, oversees McKinsey’s Medical Affairs Performance Evaluation Survey and hosts Medical Affairs leadership round-tables. Mr. van Overbeeke started with McKinsey in the Netherlands, and since then has served pharmaceutical and medical device companies across Europe, the US and Asia during his 3 year tenure in the United Kingdom and since 2014 in Japan. A native of the Netherlands, Mr. van Overbeeke received his Engineering degree from the Technical University of Delft and his law degree from the University of Leiden. He completed a full-time MBA program at INSEAD in Singapore and France.
Milana Zivkov
Milana Zivkov is a Senior Director, Insights & Training Global Lead, Medical Affairs, Astellas, located in Northbrook, IL, USA. She has been with Astellas since 2013 in various roles of increasing responsibility within Scientific Publications in Medical Affairs. She was instrumental in establishing Scientific Publications as a strategic partner across M & D, and from 01 July 2018, in new her new role, she is responsible for setting up Insights & Training function within Astellas. She has MD and MSc (Clinical Pharmacology) degrees from University of Belgrade Medical School, and is a fully trained neuropsychiatrist. Following a career in clinical psychiatry, Milana has worked in the pharmaceutical industry for more than 20 years holding positions in various Medical Affairs.
Anna Walz
Anna Walz is a 25+ year veteran in the pharmaceutical industry. She is the Founder and CEO Emeritus of MedEvoke, a MEDISTRAVA Company (Medical Division of Huntsworth). MedEvoke is a global medical consulting firm dedicated to working with Medical Affairs leaders to drive alignment through development of clear medical strategies that can be globally communicated, measured, and analyzed. This has, for the first time, enabled Medial Affairs to track the impact of internal efforts on the external scientific and digital exchanges.
Anna currently serves as Senior Strategic Advisor to MEDISTRAVA and provides professional guidance on the formation of a cross-company Medical Analytics Function that will overlay the community of medical affairs agencies within the healthcare division of Huntsworth. Her external responsibilities include working with key clients and professional organizations on market implementation and validation of the medical analytics function. Internal responsibilities include providing input on annual strategy planning process and relevant roll-out workstreams. Anna also serves of the Board of Directors for Healios AG, a Swiss-based medical device software manufacturer that is dedicated to finding solutions in clinical research and patient monitoring through innovative digital technologies.
Anna, who often speaks on the topics of medical strategy, launch excellence, impact metrics for medical affairs, female entrepreneurship, and diversity in the biosciences, is also a regular guest-lecturer on the topic of Pharmacology & Drug Marketing at the Rutgers Medical School. In addition to speaking, Anna has a keen interest in her own continuing education and is a graduate of both the Tuck-WBENC Executive Education program and the Entrepreneurial Master’s Program (EMP), a joint collaboration of the Entrepreneurs’ Organization (EO) and the Massachusetts Institute of Technology (MIT).
Anna has been one of the most vocal champions for MAPS since its inception, has served as Co-Chair of the Standards & Guidance Committee, and is currently serving on the organization’s Board of Directors and on the Fund Development Committee.
Iris Loew-Friedrich
Prof. Dr. med. Iris Loew-Friedrich is Chief Medical Officer for UCB, a member of the company’s Executive Committee and Head of Development Solutions. She provides strategic global leadership for world-wide clinical development, medical affairs, regulatory affairs, statistical innovation, real world evidence, patient safety/pharmacovigilance and quality assurance. Iris started her service for patients in the pharmaceutical industry in 1992 with a focus on clinical development in the areas of immunology, bone disease and neurology, delivering together with her teams several novel medicines to patients. She held various positions in Research and Development in different companies, always with a focus on global drug development. Since 2001, prior to joining UCB, Iris was the Global Head of Research and Development at Schwarz Pharma (acquired by UCB in 2006) and a member of their Executive Committee. Iris is a physician, board-certified in internal medicine, with a medical license from the University of Frankfurt where she also holds a visiting professorship at the Medical School. Iris is active in industry associations, a member of different supervisory boards, including the board of TransCelerate and PhRMA Foundation. She is passionate about making a difference to the lives of people living with severe diseases.